High-end partnerships and AI support to solve complex problems support the silent climb of altcoin Vectorspace AI (VXV) price to ATH levels. In addition, the KuCoin listing also confirmed the demand from its investors. Let’s start with Vectorspace’s recent price movements, the project’s functionalities will be our next stops.
What is Vectorspace AI (VXV)?
Vectorspace AI (VXV) is a set of protocol-building correlation matrix and datasets whose graphs can detect hidden relationships in data and do artificial training without the need to jump to DeFi or NFT trending. VXV price is down 2% on September 16, before suffering a significant pullback along with the rest of the crypto market since it dropped to $0.71 on May 23, according to data from TradingView. It rose 267 to reach a record high of $19.47.
Altcoin VXV listed on Kucoin
This week, the price action for VXV is 32%, with 24-hour volume up 380% to $9.37 million on Nov. It hit an intraday high of $16.18 with an increase of 42. The spike in price and trading volume comes after being listed on KuCoin, the sixth largest cryptocurrency exchange by trading volume.
https://twitter. com/Vectorspace_AI/status/1458823602657284097
Besides the tweet above announcing the KuCoin listing, the Vectorspace AI team maintains a pretty low-key profile in terms of project announcements and marketing. Many of the project’s Twitter posts feature some of the latest developments and discoveries in data analysis and bioscience.
https://twitter. com/Vectorspace_AI/status/1436280182957035559
But for anyone who pays attention to the increasing value and importance of data in the digital age, the ability to correlate and analyze large amounts of data to discover solutions that would take human years to analyze manually is among the biggest problems in the world to solve. For example, early in the COVID-19 pandemic, Vectorspace technology helped scientists narrow down their research and save valuable time by analyzing years of medical research and findings to recommend a short list of substances that could be used as treatments.
PubMed among existing partners and collaborators, according to the project’s website. gov, the United States Department of Energy, the National Library of Medicine, the European Molecular Biology Laboratory, Lawrence Berkeley National Laboratory, and CERN.
